The North America Myasthenia Gravis Treatment Market would witness market growth of 8.7% CAGR during the forecast period (2023-2030).
Technological advancements are enabling remote patient monitoring and the collection of real-time data, enhancing disease management and treatment adjustment for MG patients. Gene and cellular therapies are being investigated as potential treatments for MG, with the prospect of long-term remission. Gene therapy involves modifying or introducing genes into a patient's cells to correct a genetic abnormality or alter the disease process. In the context of MG, gene therapy is being explored as a potential way to target the immune system dysfunction underlying the condition.
Gene therapy tries to change the activity of specific immune system cells, like T cells or B cells, to limit the creation of autoantibodies that assault the neuromuscular junction. Autoantibodies attack the neuromuscular junction. This could lessen the immune response against the patient's tissues, addressing the root cause of MG. Introducing genes that regulate the immune response could help restore immune tolerance, reducing the attack on the neuromuscular junction and thus preventing muscle weakness and fatigue.
The United States has one of the highest healthcare spending levels per capita. Factors contributing to high healthcare spending include the cost of medical procedures, pharmaceuticals, and administrative expenses. While the United States relies on both public and private healthcare finance, Canada has a publicly supported healthcare system. Government involvement is a significant factor in healthcare spending and investment in both countries. As per the data given by the United States Centres for Medicare and Medicaid Services, healthcare spending in the United States rose 2.7% in 2021, amounting to $4.3 trillion, or $12,914 per person. Growing investment in healthcare services across countries in North America will boost the demand for treatments in the region.
The US market dominated the North America Myasthenia Gravis Treatment Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,255.4 Million by 2030. The Canada market is experiencing a CAGR of 11.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 10.2% during (2023 - 2030).
Based on End-use, the market is segmented into Hospitals, Clinics and Others. Based on Type, the market is segmented into Monoclonal Antibodies, Thymectomy, Cholinesterase Inhibitors, Chronic Immunomodulators, Rapid Immunotherapies and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Myasthenia Gravis Treatment Market is Predict to reach $3.8 Billion by 2030, at a CAGR of 9.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), Octapharma AG, Novartis AG, Pfizer, Inc., Allergan PLC (AbbVie, Inc.), F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Bausch Health Companies Inc., Kedrion S.p.A, and Zydus Lifesciences Ltd.
Scope of the Study
Market Segments Covered in the Report:
By End-use
By Type
- Monoclonal Antibodies
- Thymectomy
- Cholinesterase Inhibitors
- Chronic Immunomodulators
- Rapid Immunotherapies
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
- Octapharma AG
- Novartis AG
- Pfizer, Inc.
- Allergan PLC (AbbVie, Inc.)
- F.Hoffmann-La Roche Ltd.
- GlaxoSmithKline PLC (GSK)
- Bausch Health Companies Inc.
- Kedrion S.p.A
- Zydus Lifesciences Ltd.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Myasthenia Gravis Treatment Market, by End-use
1.4.2 North America Myasthenia Gravis Treatment Market, by Type
1.4.3 North America Myasthenia Gravis Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. North America Myasthenia Gravis Treatment Market by End-use
4.1 North America Hospitals Market by Country
4.2 North America Clinics Market by Country
4.3 North America Others Market by Country
Chapter 5. North America Myasthenia Gravis Treatment Market by Type
5.1 North America Monoclonal Antibodies Market by Country
5.2 North America Thymectomy Market by Country
5.3 North America Cholinesterase Inhibitors Market by Country
5.4 North America Chronic Immunomodulators Market by Country
5.5 North America Rapid Immunotherapies Market by Country
5.6 North America Others Market by Country
Chapter 6. North America Myasthenia Gravis Treatment Market by Country
6.1 US Myasthenia Gravis Treatment Market
6.1.1 US Myasthenia Gravis Treatment Market by End-use
6.1.2 US Myasthenia Gravis Treatment Market by Type
6.2 Canada Myasthenia Gravis Treatment Market
6.2.1 Canada Myasthenia Gravis Treatment Market by End-use
6.2.2 Canada Myasthenia Gravis Treatment Market by Type
6.3 Mexico Myasthenia Gravis Treatment Market
6.3.1 Mexico Myasthenia Gravis Treatment Market by End-use
6.3.2 Mexico Myasthenia Gravis Treatment Market by Type
6.4 Rest of North America Myasthenia Gravis Treatment Market
6.4.1 Rest of North America Myasthenia Gravis Treatment Market by End-use
6.4.2 Rest of North America Myasthenia Gravis Treatment Market by Type
Chapter 7. Company Profiles
7.1 AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approval and Trails:
7.1.6 SWOT Analysis
7.2 Octapharma AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.3 Novartis AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 SWOT Analysis
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approval and Trails:
7.4.6 SWOT Analysis
7.5 Allergan PLC (AbbVie, Inc.)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.1 Research & Development Expense
7.5.2 SWOT Analysis
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 SWOT Analysis
7.7 GlaxoSmithKline PLC (GSK)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 SWOT Analysis
7.8 Bausch Health Companies Inc
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 SWOT Analysis
7.9 Kedrion S.p.A
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 SWOT Analysis
7.10. Zydus Lifesciences Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 SWOT Analysis
TABLE 1 North America Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 2 North America Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 3 North America Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 4 North America Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 5 North America Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 6 North America Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 7 North America Clinics Market by Country, 2019 - 2022, USD Million
TABLE 8 North America Clinics Market by Country, 2023 - 2030, USD Million
TABLE 9 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 10 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 11 North America Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 12 North America Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 13 North America Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 14 North America Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 15 North America Thymectomy Market by Country, 2019 - 2022, USD Million
TABLE 16 North America Thymectomy Market by Country, 2023 - 2030, USD Million
TABLE 17 North America Cholinesterase Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 18 North America Cholinesterase Inhibitors Market by Country, 2023 - 2030, USD Million
TABLE 19 North America Chronic Immunomodulators Market by Country, 2019 - 2022, USD Million
TABLE 20 North America Chronic Immunomodulators Market by Country, 2023 - 2030, USD Million
TABLE 21 North America Rapid Immunotherapies Market by Country, 2019 - 2022, USD Million
TABLE 22 North America Rapid Immunotherapies Market by Country, 2023 - 2030, USD Million
TABLE 23 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 24 North America Others Market by Country, 2023 - 2030, USD Million
TABLE 25 North America Myasthenia Gravis Treatment Market by Country, 2019 - 2022, USD Million
TABLE 26 North America Myasthenia Gravis Treatment Market by Country, 2023 - 2030, USD Million
TABLE 27 US Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 28 US Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 29 US Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 30 US Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 31 US Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 32 US Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 33 Canada Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 34 Canada Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 35 Canada Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 36 Canada Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 37 Canada Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 38 Canada Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 39 Mexico Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 40 Mexico Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 41 Mexico Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 42 Mexico Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 43 Mexico Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 44 Mexico Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 45 Rest of North America Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 46 Rest of North America Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 47 Rest of North America Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 48 Rest of North America Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 49 Rest of North America Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 50 Rest of North America Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 51 KEY INFORMATION – ASTRAZENECA PLC
TABLE 52 Key Information – Octapharma AG
TABLE 53 Key Information – Novartis AG
TABLE 54 Key Information – Pfizer, Inc.
TABLE 55 Key Information – Allergan PLC
TABLE 56 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 57 Key Information – GlaxoSmithKline PLC
TABLE 58 Key Information – Bausch Health Companies Inc
TABLE 59 key Information – Kedrion S.p.A
TABLE 60 Key Information – Zydus Lifesciences Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 North America Myasthenia Gravis Treatment Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Myasthenia Gravis Treatment Market
FIG 4 Porter’s Five Forces Analysis – Myasthenia Gravis Treatment Market
FIG 5 North America Myasthenia Gravis Treatment Market share by End-use, 2022
FIG 6 North America Myasthenia Gravis Treatment Market share by End-use, 2030
FIG 7 North America Myasthenia Gravis Treatment Market by End-use, 2019 - 2030, USD Million
FIG 8 North America Myasthenia Gravis Treatment Market share by Type, 2022
FIG 9 North America Myasthenia Gravis Treatment Market share by Type, 2030
FIG 10 North America Myasthenia Gravis Treatment Market by Type, 2019 - 2030, USD Million
FIG 11 North America Myasthenia Gravis Treatment Market share by Country, 2022
FIG 12 North America Myasthenia Gravis Treatment Market share by Country, 2030
FIG 13 North America Myasthenia Gravis Treatment Market by Country, 2019 - 2030, USD Million
FIG 14 SWOT Analysis: AstraZeneca PLC
FIG 15 SWOT Analysis: Novartis AG
FIG 16 SWOT Analysis: Pfizer, Inc.
FIG 17 SWOT Analysis: Allergan PLC
FIG 18 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 19 SWOT Analysis: GlaxoSmithKline PLC
FIG 20 SWOT Analysis: Bausch Health Companies Inc
FIG 21 SWOT Analysis: Kedrion S.p.A
FIG 22 SWOT Analysis: Zydus Lifesciences Ltd.